Checkmate Pharmaceuticals, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Checkmate Pharmaceuticals, Inc. | CMPI - NASDAQ |
$14.00-$16.00 | $15.00 | $14.90 | 5 million | 8/7/2020 |
| BofA Securities, Jefferies, BMO Capital Markets | ||||||
Co-Manager(s): BTIG | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-07-17 Terms Added 2020-08-03 | ||||||
Checkmate Pharmaceuticals, Inc. Quote & Chart - Click for current quote - CMPI
IPO Boutique aggregates information on public companies and private companies, such as "CMPI" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Checkmate Pharmaceuticals, Inc. (adapted from Checkmate Pharmaceuticals, Inc. prospectus):
They are a clinical-stage biotechnology company focused on developing and commercializing our proprietary technology to harness the power of the immune system to combat cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biotechnology company focused on developing and commercializing our proprietary technology to harness the power of the immune system to combat cancer.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "CMPI" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.